Patents Assigned to Sumitomo Dainippon Pharma Co., Ltd.
-
Publication number: 20190070122Abstract: To provide to a transdermal absorption-type patch preparation containing zonisamide, that is a transdermal absorption-type patch preparation containing zonisamide or an alkali metal salt thereof, being capable of maintaining a high concentration of a drug in a dissolved state in the preparation and exhibiting sufficient and sustained drug efficacy. A transdermal absorption-type patch preparation containing an adhesive layer, the adhesive layer containing zonisamide or an alkali metal salt thereof, an adhesive agent containing a (meth)acrylic copolymer having a pyrrolidone group, and a transdermal absorption promoter containing N-alkylpyrrolidone.Type: ApplicationFiled: March 24, 2017Publication date: March 7, 2019Applicants: TEIKOKU SEIYAKU CO., LTD., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Katsuyuki INOO, Daiki TAKANO
-
Publication number: 20190062294Abstract: Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of a 2-alkylcarbonyl[2,3-b]furan-4,9-dione, which comprises reacting a 1-butyne derivative in which a ketone or an alcohol is protected with a 2-hydroxy-1,4-naphthoquinone derivative having a leaving group at position-3 in a solvent in the presence of a metal or a metal compound and a base; and a substance relating to the intermediate.Type: ApplicationFiled: March 24, 2017Publication date: February 28, 2019Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Kazuhiko TAKAHASHI, Shoji WATANABE, Katsuya UCHIYAMA, Kento SENAMI
-
Publication number: 20190054141Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.Type: ApplicationFiled: August 23, 2018Publication date: February 21, 2019Applicants: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
-
Publication number: 20190030149Abstract: A compound represented by the formula (1): wherein Xa and Ya are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R1 is a hydrogen atom, a group represented by the formula (2): wherein Xb and Yb are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.Type: ApplicationFiled: October 17, 2018Publication date: January 31, 2019Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Chiang Jia LI, Hitoshi Ban, Yukihiro Nishio, Masashi Goto, Toshio Nishihara, Yosuke Takanashi
-
Publication number: 20190022091Abstract: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.Type: ApplicationFiled: September 24, 2018Publication date: January 24, 2019Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Kazuhito Ikeda, Takeo Ishiyama
-
Patent number: 10183925Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: GrantFiled: March 25, 2016Date of Patent: January 22, 2019Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Patent number: 10183913Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.Type: GrantFiled: May 25, 2018Date of Patent: January 22, 2019Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
-
Publication number: 20190016711Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: ApplicationFiled: January 12, 2017Publication date: January 17, 2019Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi WATANABE, Yoshiaki ISOBE, Hidenori KIMURA, Yuji FUJIWARA
-
Publication number: 20190010149Abstract: The present invention relates to a composition comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1?R,2?S,3?R,4?S)-2,3-bicyclo[2,2,1]heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof. In detail, the composition relates to a sustained release formulation for injection which maintains an effective blood level of the above-mentioned compound.Type: ApplicationFiled: September 12, 2018Publication date: January 10, 2019Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Takashi NAKAGAWA, Norimasa Koseki
-
Publication number: 20180353485Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 25, 2016Publication date: December 13, 2018Applicants: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
-
Patent number: 10150743Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.Type: GrantFiled: May 11, 2016Date of Patent: December 11, 2018Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
-
Publication number: 20180344831Abstract: The present invention provides an injectable pharmaceutical composition containing the following components: (a) one or more kinds of peptides selected from a peptide represented by the formula (1): wherein the bond between Cys and Cys is a disulfide bond, Leu-OH shows that the C-terminal of Leu is a free carboxyl group, and other bond is a peptide bond, a peptide consisting of the amino acid sequence shown by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and salts thereof, (b) trehalose or trehalose hydrate, and (c) a pH adjuster.Type: ApplicationFiled: September 26, 2015Publication date: December 6, 2018Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Satoshi TANAKA, Tomomi NAKATANI
-
Publication number: 20180349672Abstract: A specific region such as a continuous epithelial structure is automatically detected in a cell aggregate. A region detecting method includes an input step (S01) of inputting an image obtained by imaging a cell aggregate, an outline detecting step (S02) of detecting an outline of the cell aggregate together with an order along the outline from the input image, a region detecting step (S03) of detecting a specific region included in the cell aggregate based on the detected outline and order, and an output step (S04) of outputting information indicating the detected region.Type: ApplicationFiled: November 25, 2016Publication date: December 6, 2018Applicants: RIKEN, Sumitomo Dainippon Pharma Co., Ltd., SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Satoru Okuda, Mototsugu Eiraku, Atsushi Kuwahara
-
Publication number: 20180344730Abstract: The present invention relates to a medicament comprising lurasidone or a pharmaceutically acceptable acid addition salt thereof for treating pervasive developmental disorders and a method of the treatment thereof.Type: ApplicationFiled: July 24, 2018Publication date: December 6, 2018Applicant: Sumitomo Dainippon Pharma Co., Ltd.Inventor: Tsuyoshi TSUJIMURA
-
Patent number: 10098875Abstract: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.Type: GrantFiled: January 13, 2016Date of Patent: October 16, 2018Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Kazuhito Ikeda, Takeo Ishiyama
-
Publication number: 20180282334Abstract: The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.Type: ApplicationFiled: September 28, 2016Publication date: October 4, 2018Applicants: Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca AktiebolagInventors: Hitoshi Ban, Yukihiro Nishio, Padma Malyala, Bilikallahalli K. Muralidhara, Marcus Wong
-
Patent number: 10087146Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.Type: GrantFiled: April 19, 2017Date of Patent: October 2, 2018Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
-
Publication number: 20180271838Abstract: The present invention provides in one embodiment a pharmaceutical composition for treating and/or preventing peripheral neuropathy or spinal cord injury comprising zonisamide or an alkali metal salt thereof as an active ingredient.Type: ApplicationFiled: September 29, 2016Publication date: September 27, 2018Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Kinji OHNO, Naoki ISHIGURO, Bisei OKAWARA, Hideki YAGI, Kyotaro OTA
-
Patent number: 10080776Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.Type: GrantFiled: May 24, 2016Date of Patent: September 25, 2018Assignees: Sapporo Medical University, Sumitomo Dainippon Pharma Co., Ltd.Inventors: Toshihiko Torigoe, Yoshihiko Hirohashi, Noriyuki Satoh, Kenjiro Kamiguchi, Rena Morita, Satoshi Nishizawa, Akari Takahashi
-
Publication number: 20180265489Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 23, 2018Publication date: September 20, 2018Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA